MX2021002455A - Metodos para tratar tumores de celulas epitelioides. - Google Patents

Metodos para tratar tumores de celulas epitelioides.

Info

Publication number
MX2021002455A
MX2021002455A MX2021002455A MX2021002455A MX2021002455A MX 2021002455 A MX2021002455 A MX 2021002455A MX 2021002455 A MX2021002455 A MX 2021002455A MX 2021002455 A MX2021002455 A MX 2021002455A MX 2021002455 A MX2021002455 A MX 2021002455A
Authority
MX
Mexico
Prior art keywords
cell tumors
methods
epithelioid cell
treating
treating epithelioid
Prior art date
Application number
MX2021002455A
Other languages
English (en)
Inventor
Neil P Desai
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57609139&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021002455(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX2021002455A publication Critical patent/MX2021002455A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona métodos y composiciones para tratar tumores de células epitelioides (como PEComa) mediante la administración de una composición que comprende nanopartículas que comprenden un inhibidor mTOR y una albúmina.
MX2021002455A 2015-06-29 2017-12-14 Metodos para tratar tumores de celulas epitelioides. MX2021002455A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562186252P 2015-06-29 2015-06-29

Publications (1)

Publication Number Publication Date
MX2021002455A true MX2021002455A (es) 2021-05-14

Family

ID=57609139

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016322A MX2017016322A (es) 2015-06-29 2016-06-29 Metodos para tratar tumores de celulas epitelioides.
MX2021002455A MX2021002455A (es) 2015-06-29 2017-12-14 Metodos para tratar tumores de celulas epitelioides.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017016322A MX2017016322A (es) 2015-06-29 2016-06-29 Metodos para tratar tumores de celulas epitelioides.

Country Status (26)

Country Link
US (2) US10973806B2 (es)
EP (2) EP3998069A1 (es)
JP (3) JP6987644B2 (es)
KR (2) KR20230165356A (es)
CN (3) CN116585310A (es)
AU (2) AU2016285720C1 (es)
BR (1) BR112017027954B1 (es)
CA (1) CA2990693C (es)
CL (1) CL2017003456A1 (es)
CY (1) CY1124926T1 (es)
DK (1) DK3313401T3 (es)
EA (2) EA202092187A1 (es)
ES (1) ES2897991T3 (es)
HK (1) HK1247094A1 (es)
HR (1) HRP20211718T1 (es)
HU (1) HUE057175T2 (es)
IL (1) IL256274B2 (es)
LT (1) LT3313401T (es)
MX (2) MX2017016322A (es)
PL (1) PL3313401T3 (es)
PT (1) PT3313401T (es)
RS (1) RS62743B1 (es)
SG (1) SG10202107198SA (es)
SI (1) SI3313401T1 (es)
WO (1) WO2017004249A1 (es)
ZA (1) ZA201708567B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007334360B2 (en) 2006-12-14 2013-10-17 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
ME03596B (me) 2009-04-15 2020-07-20 Abraxis Bioscience Llc Kompozicije nanočesтica bez priona i postupci povezani sa njima
US10660965B2 (en) 2010-03-29 2020-05-26 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
SG194623A1 (en) 2011-04-28 2013-12-30 Abraxis Bioscience Llc Intravascular delivery of nanoparticle compositions and uses thereof
MX354859B (es) 2011-12-14 2018-03-23 Abraxis Bioscience Llc Uso de excipientes polimericos para liofilizacion o congelacion de particulas.
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
CN110934852A (zh) 2013-03-14 2020-03-31 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CN116585310A (zh) 2015-06-29 2023-08-15 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
EP3768268A4 (en) 2018-03-20 2022-02-23 Abraxis BioScience, LLC METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE
WO2019226685A1 (en) * 2018-05-22 2019-11-28 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
CN109182519B (zh) * 2018-09-17 2019-06-14 中国人民解放军南京军区南京总医院 一种用于诊断acta2-mitf易位性血管周上皮样细胞肿瘤的探针组合及其应用
WO2020191053A1 (en) * 2019-03-19 2020-09-24 Abraxis Bioscience, Llc Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases
KR20220106758A (ko) 2019-10-28 2022-07-29 아브락시스 바이오사이언스, 엘엘씨 알부민 및 라파마이신의 제약 조성물
US20230000844A1 (en) * 2019-11-11 2023-01-05 Abraxis Bioscience, Llc Biomarkers for nanoparticle compositions
WO2021096997A1 (en) * 2019-11-11 2021-05-20 Abraxis Bioscience, Llc Biomarkers for nanoparticle compositions
CN116600789A (zh) * 2020-06-19 2023-08-15 耶鲁大学 用于诱导耐受性的聚合胆汁酸酯纳米颗粒

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US20030068362A1 (en) 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US20070122465A1 (en) 1993-02-22 2007-05-31 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5997904A (en) 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
ES2219646T5 (es) 1993-02-22 2008-11-01 Abraxis Bioscience, Inc. Metodos para la administracion in vivo de compuestos biologicos y composiciones utiles para los mismos.
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US6565842B1 (en) 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
JP4865937B2 (ja) 1997-06-27 2012-02-01 アブラクシス バイオサイエンス、エルエルシー パクリタキセル製剤
US20030199425A1 (en) 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
AU777528B2 (en) 1999-04-22 2004-10-21 Abraxis Bioscience, Llc Long term administration of pharmacologically active agents
WO2000071079A2 (en) 1999-05-21 2000-11-30 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
ITMI20001107A1 (it) 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
ITMI20020681A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
US20050004002A1 (en) 2002-12-09 2005-01-06 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
WO2004052401A2 (en) 2002-12-09 2004-06-24 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
RU2452482C2 (ru) 2005-02-18 2012-06-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Комбинация и способы введения терапевтических средств и комбинированной терапии
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
TWI429452B (zh) 2005-08-31 2014-03-11 Abraxis Bioscience Llc 包含弱水溶性藥劑及抗微生物劑之組合物
EP3527202A1 (en) 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
MX2008012715A (es) 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
US20080280987A1 (en) 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
WO2008027055A1 (en) 2006-08-31 2008-03-06 Abraxis Bioscience, Llc Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
US20100112077A1 (en) 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
AU2007334360B2 (en) 2006-12-14 2013-10-17 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
AU2013204187B2 (en) 2007-03-07 2015-10-01 Abraxis Bioscience, Llc Nanoparticle comprising rapamycin and albumin as anticancer agent
CN101730526A (zh) 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
JP2010520289A (ja) 2007-03-07 2010-06-10 アブラクシス バイオサイエンス， エルエルシー 抗癌剤としてラパマイシンおよびアルブミンを含むナノ粒子
WO2008137148A2 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
AU2008260447B2 (en) 2007-06-01 2013-10-10 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer
KR20150136137A (ko) 2008-04-10 2015-12-04 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 및 그의 용도
CA2721153C (en) 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
WO2010118365A1 (en) 2009-04-10 2010-10-14 Abraxis Bioscience, Llc Nanoparticle formulations and uses therof
ES2668837T3 (es) 2008-12-11 2018-05-22 Abraxis Bioscience, Llc Terapia de combinación que incluye un taxano y un agente terapéutico adicional
WO2010083298A1 (en) 2009-01-14 2010-07-22 Health Research Inc. Methods and compositions containing mtor inhibitors for enhancing immune responses
BRPI1008955A2 (pt) 2009-03-13 2015-09-01 Abraxis Bioscience Llc Terapia de combinação com derivados de tiocolchicina.
ME03596B (me) 2009-04-15 2020-07-20 Abraxis Bioscience Llc Kompozicije nanočesтica bez priona i postupci povezani sa njima
SG178873A1 (en) 2009-08-25 2012-04-27 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
NZ602382A (en) 2010-03-26 2014-11-28 Abraxis Bioscience Llc Methods of treatment of hepatocellular carcinoma
US10660965B2 (en) 2010-03-29 2020-05-26 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
SI2552415T1 (sl) 2010-03-29 2017-03-31 Abraxis Bioscience, Llc Metode za zdravljenje raka
JP2013527232A (ja) 2010-06-02 2013-06-27 アブラクシス バイオサイエンス， エルエルシー 膀胱がんの処置方法
SG186112A1 (en) 2010-06-04 2013-01-30 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
CA2801891C (en) 2010-06-07 2020-10-27 Abraxis Bioscience, Llc Combination therapy methods for treating proliferative diseases
SG194623A1 (en) 2011-04-28 2013-12-30 Abraxis Bioscience Llc Intravascular delivery of nanoparticle compositions and uses thereof
MX354859B (es) 2011-12-14 2018-03-23 Abraxis Bioscience Llc Uso de excipientes polimericos para liofilizacion o congelacion de particulas.
US9212224B2 (en) 2012-05-15 2015-12-15 Bristol-Myers Squibb Company Antibodies that bind PD-L1 and uses thereof
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
US20140199404A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on level of a nucleoside transporter
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
NZ630239A (en) 2013-02-11 2017-08-25 Abraxis Bioscience Llc Methods of treating melanoma
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
EP2968253A4 (en) 2013-03-13 2016-11-02 Abraxis Bioscience Llc METHODS OF TREATING PEDIATRIC SOLID TUMOR
CN110934852A (zh) 2013-03-14 2020-03-31 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
US20160015691A1 (en) 2013-03-15 2016-01-21 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth
JP6389241B2 (ja) 2013-04-17 2018-09-12 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのＴＯＲキナーゼ阻害剤及びＩＭｉＤ化合物を含む組合せ療法
WO2015157120A1 (en) 2014-04-06 2015-10-15 Abraxis Bioscience, Llc Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US20180064679A1 (en) 2015-03-05 2018-03-08 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
CN107921050A (zh) 2015-06-29 2018-04-17 阿布拉科斯生物科学有限公司 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
AU2016285727B9 (en) 2015-06-29 2021-09-30 Abraxis Bioscience, Llc Biomarkers for nanoparticle compositions
CN116585310A (zh) 2015-06-29 2023-08-15 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
KR20180019229A (ko) 2015-06-29 2018-02-23 아브락시스 바이오사이언스, 엘엘씨 나노입자 mTOR 억제제 조합 요법을 사용하여 고형 종양을 치료하는 방법
US20170181988A1 (en) 2015-12-23 2017-06-29 Cipla Limited Methods for the treatment of bladder cancer
US20190147986A1 (en) 2016-05-17 2019-05-16 Abraxis Bioscience, Llc Methods for assessing neoadjuvant therapies
KR102475256B1 (ko) 2016-09-28 2022-12-08 아브락시스 바이오사이언스, 엘엘씨 미토콘드리아 및 대사 장애를 치료하는 방법
BR112019006329A2 (pt) 2016-10-07 2019-06-25 Abraxis Bioscience Llc métodos de tratamento de câncer do trato biliar
WO2018071399A1 (en) 2016-10-10 2018-04-19 Abraxis Bioscience, Llc Nanoparticle formulations and methods of making and using thereof
US20180374583A1 (en) 2017-05-16 2018-12-27 Abraxis Bioscience, Llc Nomogram and survival predictions for pancreatic cancer
CN111683657A (zh) 2017-12-19 2020-09-18 阿布拉科斯生物科学有限公司 利用纳米颗粒mTOR抑制剂联合疗法治疗结肠癌的方法

Also Published As

Publication number Publication date
EP3313401A1 (en) 2018-05-02
IL256274B2 (en) 2023-02-01
EP3998069A1 (en) 2022-05-18
PL3313401T3 (pl) 2022-02-07
JP6987644B2 (ja) 2022-01-05
PT3313401T (pt) 2021-11-17
BR112017027954B1 (pt) 2023-10-03
EA202092187A1 (ru) 2021-08-31
CY1124926T1 (el) 2023-01-05
HRP20211718T1 (hr) 2022-03-04
MX2017016322A (es) 2018-05-02
SG10202107198SA (en) 2021-08-30
CN116585310A (zh) 2023-08-15
JP7351888B2 (ja) 2023-09-27
KR102606071B1 (ko) 2023-11-27
ES2897991T3 (es) 2022-03-03
RS62743B1 (sr) 2022-01-31
US20180177770A1 (en) 2018-06-28
EP3313401B1 (en) 2021-10-06
LT3313401T (lt) 2022-01-10
CA2990693C (en) 2024-02-27
CN108024999A (zh) 2018-05-11
KR20230165356A (ko) 2023-12-05
CN116473964A (zh) 2023-07-25
EA201890157A1 (ru) 2018-09-28
EA036790B1 (ru) 2020-12-22
AU2021286245B2 (en) 2024-01-18
IL256274A (en) 2018-02-28
JP2023175811A (ja) 2023-12-12
AU2016285720C1 (en) 2022-02-03
EP3313401A4 (en) 2019-02-13
DK3313401T3 (da) 2021-11-15
AU2016285720B2 (en) 2021-09-30
SI3313401T1 (sl) 2022-04-29
CA2990693A1 (en) 2017-01-05
HK1247094A1 (zh) 2018-09-21
BR112017027954A2 (pt) 2018-08-28
US20210322391A1 (en) 2021-10-21
JP2018521057A (ja) 2018-08-02
ZA201708567B (en) 2021-03-31
AU2016285720A1 (en) 2018-02-01
US10973806B2 (en) 2021-04-13
JP2022043090A (ja) 2022-03-15
IL256274B (en) 2022-10-01
WO2017004249A1 (en) 2017-01-05
NZ738936A (en) 2023-08-25
KR20180021836A (ko) 2018-03-05
HUE057175T2 (hu) 2022-04-28
AU2021286245A1 (en) 2022-01-06
CL2017003456A1 (es) 2018-05-11

Similar Documents

Publication Publication Date Title
MX2021002455A (es) Metodos para tratar tumores de celulas epitelioides.
MX2015011753A (es) Metodos para tratar cancer de vegija.
MX2018006217A (es) Agonistas del receptor de apelina y metodos de uso.
MX2023013010A (es) Composiciones con nanoparticulas que comprenden sirolimus y albumina para usarse en el tratamiento de cancer relacionado con una aberracion activante de m-tor.
MX2015008889A (es) Metodo para tratar cancer con base en el estado de la mutacion k-ras.
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
PH12017500660A1 (en) Novel compositions, uses and methods for making them
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
MY189454A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
MX2015008888A (es) Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.
MX2016006316A (es) Inhibidores de mtor para potenciar la respuesta inmunitaria.
MX2018004344A (es) 2,4-dihidroxi-nicotinamidas como agonistas del recepor de apelina (apj).
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
TR201900071T4 (tr) Kontrollü Over Stimülasyonuna Yönelik Bileşim
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
PH12017501864A1 (en) Compositions and methods for treating autism
MX2017013360A (es) Métodos para tratar el cáncer.
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
BR112015023383A2 (pt) compostocomposição farmacêutica; e método de modulação
MX2017011116A (es) Composiciones novedosas, usos y metodos para hacerlas.
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2017017119A (es) Formulacion de alta concentracion.